Predictors of thromboembolic complications in patients with severe SARS-CoV-2 coronavirus infection
- Authors: Podzolkov V.I.1, Volchkova E.V.1, Tarzimanova A.I.1, Bragina A.E.1, Ivannikov A.A.1, Bykova E.E.1, Shvedov I.I.1, Oganesyan K.A.1, Isaeva A.Y.1
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 95, No 11 (2023)
- Pages: 907-912
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/231994
- DOI: https://doi.org/10.26442/00403660.2023.11.202472
- ID: 231994
Cite item
Full Text
Abstract
Aim. To identify predictors of the development of thromboembolic complications (TECs) in patients with severe SARS-CoV-2 coronavirus infection.
Materials and methods. A single-center observational retrospective study included 1634 patients with a confirmed diagnosis of SARS-CoV-2 coronavirus infection. The patients were divided into 2 groups depending on the availability of the feasibility study. The criterion for inclusion of patients in the main group was the presence of venous feasibility studies in 127 patients (group I), the comparison group consisted of 1507 patients in whom the course of COVID-19 was not complicated by the development of feasibility studies (group II).
Results. When performing computed tomography of the chest organs, it was revealed that patients with a feasibility study had a higher percentage of lung tissue damage than patients in the comparison group: 55% [37.5; 67.5] and 37.5% [25.0; 47.5], respectively (p<0.001). The average values of C-reactive protein in I patients group were 129 [60.1; 211] ng/l, which was significantly higher than in II patients group – 41.0 [12.2; 97.6] ng/l (p<0.001), interleukin-6 – 176 [52.9; 471] pg/ml and 39.4 [11.0; 107] pg/ml (p<0.001), respectively. A one-factor regression analysis proved a significant contribution of comorbid pathology to the development of feasibility studies in patients with COVID-19. The presence of three nosologies at the same time: arterial hypertension, coronary heart disease (CHD) and chronic kidney disease increased the probability of a feasibility study by 4.81 times (odds ratio 4.8117, 95% confidence interval 3.2064–7.2207), in patients with arterial hypertension, CHD, chronic kidney disease and type 2 diabetes – by 5.63 times (odds ratio 5.6321, 95% confidence interval 3.1870–9.9531).
Conclusion. The presence of severe comorbid pathology significantly increased the risk of developing a feasibility study in patients with COVID-19. The most significant predictors of the development of feasibility studies in patients with severe SARS-CoV-2 coronavirus infection. They are: CHD, arterial hypertension and type 2 diabetes.
Full Text
##article.viewOnOriginalSite##About the authors
Valery I. Podzolkov
Sechenov First Moscow State Medical University (Sechenov University)
Email: tarzimanova@mail.ru
ORCID iD: 0000-0002-0758-5609
доктор мед. наук, проф., зав. каф. факультетской терапии №2, директор клиники факультетской терапии №2 Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowElena V. Volchkova
Sechenov First Moscow State Medical University (Sechenov University)
Email: tarzimanova@mail.ru
ORCID iD: 0000-0002-6578-1026
доктор мед. наук, проф., зав. каф. инфекционных болезней Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowAida I. Tarzimanova
Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: tarzimanova@mail.ru
ORCID iD: 0000-0001-9536-8307
доктор мед. наук, проф. каф. факультетской терапии №2 Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowAnna E. Bragina
Sechenov First Moscow State Medical University (Sechenov University)
Email: tarzimanova@mail.ru
ORCID iD: 0000-0002-2699-1610
доктор мед. наук, проф. каф. факультетской терапии №2 Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowAlexander A. Ivannikov
Sechenov First Moscow State Medical University (Sechenov University)
Email: tarzimanova@mail.ru
ORCID iD: 0000-0002-9738-1801
аспирант каф. факультетской терапии №2 Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowEkaterina E. Bykova
Sechenov First Moscow State Medical University (Sechenov University)
Email: tarzimanova@mail.ru
ORCID iD: 0000-0002-4830-624X
ассистент каф. факультетской терапии №2 Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowIlya I. Shvedov
Sechenov First Moscow State Medical University (Sechenov University)
Email: tarzimanova@mail.ru
ORCID iD: 0000-0001-9722-6097
аспирант каф. факультетской терапии №2 Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowKarine A. Oganesyan
Sechenov First Moscow State Medical University (Sechenov University)
Email: tarzimanova@mail.ru
ORCID iD: 0000-0003-3580-7229
зав. терапевтическим отд-нием клиники факультетской терапии №2 Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowAlena Y. Isaeva
Sechenov First Moscow State Medical University (Sechenov University)
Email: tarzimanova@mail.ru
ORCID iD: 0009-0002-2562-172X
клинический ординатор каф. факультетской терапии №2 Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowReferences
- Cohen SL, Gianos E, Barish MA, et al. Prevalence and predictors of venous thromboembolism or mortality in hospitalized COVID-19 patients. Thromb Haemost. 2021;121(8):1043-53. doi: 10.1055/a-1366-9656
- Le Jeune S, Suhl J, Benainous R, et al. High prevalence of early asymptomatic venous thromboembolism in anticoagulated COVID-19 patients hospitalized in general wards. J Thromb Thrombolysis. 2021;51(3):637-41. doi: 10.1007/s11239-020-02246-w
- Zuin M, Engelen MM, Bilato C, et al. Prevalence of acute pulmonary embolism at autopsy in patients with COVID-19. Am J Cardiol. 2022;171:159-64. doi: 10.1016/j.amjcard.2022.01.051
- Петриков С.С., Иванников А.А., Васильченко М.К, и др. COVID-19 и сердечно-сосудистая система. Часть 1. Патофизиология, патоморфология, осложнения, долгосрочный прогноз. Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь». 2021;10(1):14-26 [Petrikov SS, Ivannikov AA, Vasilchenko MK, et al. COVID-19 and Cardiovascular System: Pathophysiology, Pathomorphology, Complications, Long-Term Prognosis. Russian Sklifosovsky Journal „Emergency Medical Care“. 2021;10(1):14-26 (in Russian)]. doi: 10.23934/2223-9022-2021-10-1-14-26
- Cheng NM, Chan YC, Cheng SW. COVID-19 related thrombosis: A mini-review. Phlebology. 2022;37(5):326-37. doi: 10.1177/02683555211052170
- Об утверждении алгоритма действий врача при поступлении в стационар пациента с подозрением на внебольничную пневмонию, коронавирусную инфекцию (COVID-19), порядка выписки из стационара пациентов с внебольничной пневмонией, коронавирусной инфекцией (COVID-19), для продолжения лечения в амбулаторных условиях (на дому). Приказ Департамента здравоохранения г. Москвы от 08.04.2020 №373 (ред. от 17.04.2020). Режим доступа: https://mosgorzdrav.ru/ru-RU/document/default/view/1245.html. Ссылка активна на 02.05.2023 [Ob utverzhdenii algoritma deistvii vracha pri postuplenii v statsionar patsienta s podozreniem na vnebol'nichnuiu pnevmoniiu, koronavirusnuiu infektsiiu (COVID-19), poriadka vypiski iz statsionara patsientov s vnebol'nichnoi pnevmoniei, koronavirusnoi infektsiei (COVID-19), dlia prodolzheniia lecheniia v ambulatornykh usloviiakh (na domu). Prikaz Departamenta zdravookhraneniia g. Moskvy ot 08.04.2020 №373 (red. ot 17.04.2020). Available at: https://mosgorzdrav.ru/ru-RU/document/default/view/1245.html. Accessed: 02.05.2023 (in Russian)].
- Власов Т.Д., Яшин С.М. Артериальные и венозные тромбозы. Всегда ли применима триада Вирхова? Регионарное кровообращение и микроциркуляция. 2022;21(1):78-86 [Vlasov TD, Yashin SM. Arterial and venous thrombosis. Is the Virchow’s triad always valid? Regional blood circulation and microcirculation. 2022;21(1):78-86 (in Russian)]. doi: 10.24884/1682-6655-2022-21-1-78-86
- Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med. 2020;383(2):120-8. doi: 10.1056/NEJMoa2015432
- Fülöp T, Larbi A, Witkowski JM. Human inflammaging. Gerontology. 2019;65(5):495-504. doi: 10.1159/000497375
- Подзолков В.И., Брагина А.Е., Тарзиманова А.И., и др. Артериальная гипертензия и неблагоприятное течение COVID-19 среди госпитализированных больных: данные когортного исследования из России. Рациональная Фармакотерапия в Кардиологии. 2023;19(1):4-10 [PodzolkovVI, Bragina AE, Tarzimanova AI, et al. Arterial Hypertension and Severe COVID-19 in Hospitalized Patients: Data from a Cohort Study. Rational Pharmacotherapy in Cardiology. 2023;19(1):4-10 (in Russian)]. doi: 10.20996/1819-6446-2023-01-10
- Подзолков В.И., Тарзиманова А.И., Брагина А.Е., и др. Предикторы возникновения фибрилляции предсердий у больных с коронавирусной инфекцией SARS-CoV-2 (COVID-19). Российский кардиологический журнал. 2022;27(7):5095 [Podzolkov VI, Tarzimanova AI, Bragina AE, et al. Predictors of atrial fibrillation in patients with COVID-19. Russian Journal of Cardiology. 2022;27(7):5095 (in Russian)]. doi: 10.15829/1560-4071-2022-5095
- Jing H, Wu X, Xiang M, et al. Pathophysiological mechanisms of thrombosis in acute and long COVID-19. Front Immunol. 2022;13:992384. doi: 10.3389/fimmu.2022.992384
- Acanfora D, Acanfora C, Ciccone MM, et al. The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases. Viruses. 2021;13(10):1904. doi: 10.3390/v13101904
- Savla SR, Prabhavalkar KS, Bhatt LK. Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management. Expert Rev Anti Infect Ther. 2021;19(11):1397-413. doi: 10.1080/14787210.2021.1915129
- Obi AT, Barnes GD, Napolitano LM, et al. Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection. J Vasc Surg Venous Lymphat Disord. 2021;9(1):23-35. doi: 10.1016/j.jvsv.2020.08.030
- Menter T, Haslbauer JD, Nienhold R, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology. 2020;77(2):198-209. doi: 10.1111/his.14134